Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
26. |
ECCT/23/04/05 | BiMVaC01 A randomised, controlled clinical trial to assess and compare the immunogenicity, safety and reactogenicity of the bivalent Omicron BA.4/BA.5 adapted, and the original Wuhan-Hu-1-strain, BNT162b2 COVID-19 vaccine formulations in healthy unvaccinated East African adults. |
Principal Investigator(s) 1. NDUNGU FRANCIS 2. Said Jongo Site(s) in Kenya KEMRI-CGMRC Kilifi |
View |
27. |
ECCT/23/04/04 | AGREE Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya 1. Ahero County Hospital (Kisumu county) 2. Alupe sub-county Hospital (Busia county) 3. Siaya County Referral Hospital (Siaya county) |
View |
28. |
ECCT/23/04/03 | ACTIV-2d/A5407 A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19 |
Principal Investigator(s) 1. Prof Abraham Mosigisi Siika Site(s) in Kenya 1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county) 2. Victoria Biomedical Research Institute, (Kisumu county) 3. Kenyatta National Hospital (Nairobi City county) 4. KEMRI CCR – BUTERE SITE (Kakamega county) 5. Kenya Medical Research Institute/Walter Reed Project (Kericho county) 6. KEMRI – AHERO Clinical Trials Units (Kisumu county) |
View |
29. |
ECCT/23/03/06 | PDMC-II Dihydroartemisinin-piperaquine and azithromycin for the post-discharge management of children with severe anaemia in Malawi, Kenya and Uganda; A, multicentre, parallel-group, two-arm, randomised, double-blind superiority trial. |
Principal Investigator(s) 1. Simon Kariuki 2. Titus Kwambai Site(s) in Kenya Jaramogi Oginga Odinga Teaching and Referral Hospital |
View |
30. |
ECCT/23/03/05 | SKY-06 A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER |
Principal Investigator(s) 1. Dr Primus Ochieng Site(s) in Kenya 1. University of Nairobi -Institute of Tropical and Infectious Diseases (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |